MBOT, US59503A2042

Microbot Medical stock at USD 0.95, 2.15 percent above its 52-week low

Published on 10/15/2026 at 19:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 0.24 million. Microbot Medical stock costs EUR 0.85 on October 15, 2026 at 7:49 p.m. CEST in after-hours trading.

Price frame and valuation

The Nasdaq quote stood 2.15 percent above the USD 0.93 52-week low on October 15, 2026.
Second-quarter revenue reached USD 0.24 million in the period ended June 30, 2026.
Microbot Medical stock costs EUR 0.85 at Lang & Schwarz on October 15, 2026 at 7:49 p.m. CEST.
Microbot Medical had a P/E of minus 3.66 and a market capitalization of USD 63.5 million on October 15, 2026.

MBOT, US59503A2042, Illustration mit AI erstellt.

Microbot Medical (ISIN US59503A2042) stock stood 2.15 percent above its USD 0.93 52-week low on October 15, 2026, with the Nasdaq quote at USD 0.95. At Lang & Schwarz, the euro quote stood at EUR 0.85 on October 15, 2026 at 7:49 p.m. CEST in after-hours trading.

Revenue reached USD 0.24 million

The latest reported operating figure points to a larger sales base than at the start of 2026. MarketBeat reported on August 11, 2026 that revenue for the second quarter of 2026 reached USD 0.24 million, above the USD 0.13 million consensus estimate. The same report listed adjusted earnings per share of minus USD 0.08 against consensus of minus USD 0.08.

Stock stays near its yearly low

The Nasdaq quote was USD 0.95 at 1:55 p.m. ET on October 15, 2026. Trading volume reached 905,164 shares, compared with an average volume of 653,617 shares. The 52-week range was USD 0.93 to USD 3.03, placing the latest Nasdaq quote 2.15 percent above the low and 68.65 percent below the high.

Valuation reflects an early-stage profile

Microbot Medical had a market capitalization of USD 63.5 million and a P/E of minus 3.66 on October 15, 2026. Its business centers on robotic endovascular surgery devices, including the LIBERTY system. The company had said on September 25, 2026 that it was expanding its sales footprint into the western United States, according to its Microbot Medical press-release page.

Comparison with peers

MBOT (Nasdaq, USD): P/E minus 3.66, market capitalization USD 63.5 million.
Intuitive Surgical (Nasdaq, USD): plus 1.65 percent, P/E 48.65, market capitalization USD 150.9 billion.
Stereotaxis (NYSE American, USD): minus 1.43 percent, P/E minus 4.17, market capitalization USD 103.7 million.

Price and company profile

Microbot Medical operates in medical devices and remains substantially smaller than Intuitive Surgical by market value. The latest revenue figure and the current Nasdaq range place the stock between commercial expansion and a still negative earnings base.

The further course of trading is shown by the continuously updated real-time quote of Microbot Medical stock.